Pseudovirus Neutralization Assay Service for SARS-CoV-2

Using our replication-deficient MLV (or MuLV, murine leukemia virus) virus systems and stable cell lines (i.e. HEK293-ACE2, vero, CHO), we could
1) constuct the pseudoviral particles pseudotyped with specified membrane protein, wildtype or with specific mutation(s);
2) study the interactions between Spike and the host cell receptor(s) in specific conditions;
3) validate the candidates that blocks the interaction between Spike and the host cell receptor;
4) screen convalescent serum samples for neutralizing antibodies;
and more...




For constructing pseudoviral particles and the related services for other viruses, please inquire: order@eEnzyme.com.

Browse for some of our existing pseudovirus-related products:  Pseudovirus & Stable Cell Line 

Browse for our recombinant protein and antibody products, i.e. neutralization antibodies, recombinant spike proteins for variants: Coronavirus Research Tools  

Selected Citation of our SARS-CoV-2 pseudoviral particles applied in COVID research:

1) A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes & Infections, May 2021.

2) Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. Vaccines, Feb. 2021.

3) Serum Antibody Profile of a Patient With Coronavirus Disease 2019 Reinfection. Clinical Infectious Diseases, Sept. 2020.